Helsinn Hlthcare Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for HELSINN HLTHCARE, and when can generic versions of HELSINN HLTHCARE drugs launch?
HELSINN HLTHCARE has five approved drugs.
There are thirty-six US patents protecting HELSINN HLTHCARE drugs.
There are four hundred and three patent family members on HELSINN HLTHCARE drugs in sixty-nine countries and twenty-six supplementary protection certificates in fifteen countries.
Summary for Helsinn Hlthcare
| International Patents: | 403 |
| US Patents: | 36 |
| Tradenames: | 3 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Helsinn Hlthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | ALOXI | palonosetron hydrochloride | INJECTABLE;INTRAVENOUS | 021372-001 | Jul 25, 2003 | DISCN | Yes | No | 9,125,905*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
| Helsinn Hlthcare | ALOXI | palonosetron hydrochloride | INJECTABLE;INTRAVENOUS | 021372-001 | Jul 25, 2003 | DISCN | Yes | No | 7,960,424*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
| Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-002 | May 28, 2021 | RX | Yes | Yes | 8,552,002 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Helsinn Hlthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | ALOXI | palonosetron hydrochloride | INJECTABLE;INTRAVENOUS | 021372-001 | Jul 25, 2003 | 5,202,333*PED | See Plans and Pricing |
| Helsinn Hlthcare | AKYNZEO | netupitant; palonosetron hydrochloride | CAPSULE;ORAL | 205718-001 | Oct 10, 2014 | 5,202,333 | See Plans and Pricing |
| Helsinn Hlthcare | ALOXI | palonosetron hydrochloride | CAPSULE;ORAL | 022233-001 | Aug 22, 2008 | 5,202,333 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Helsinn Hlthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2016147868 | See Plans and Pricing |
| European Patent Office | 1035115 | See Plans and Pricing |
| Japan | 2013512956 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Helsinn Hlthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2785706 | 122020000050 | Germany | See Plans and Pricing | PRODUCT NAME: FOSNETUPITANT; REGISTRATION NO/DATE: C(2020)1804(FINAL) 20200316 |
| 1035115 | 2015/030 | Ireland | See Plans and Pricing | PRODUCT NAME: NETUPITANT OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1001 20150527 |
| 2785706 | CA 2020 00028 | Denmark | See Plans and Pricing | PRODUCT NAME: FOSNETUPITANT OG FARMACEUTISK ACCEPTABLE SALTE ELLER SOLVATER HERAF, SAERLLIGT FOSNETUPITANT KLORID HYDROKLORID; REG. NO/DATE: EU/1/15/1001 20200318 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
